gene therapy
-
The resignation letter of FDA CBER Director Peter Marks, MD, PhD
For more reports, please follow DrugTimes
-
FDA CBER主任Peter Marks博士的辞职信（附：中英文版本）
仅供感兴趣的专业人士朋友们个人谨慎参考。欢迎大家对中文译文进行批评指正！
-
The “Hidden Reasons” Behind WuXi AppTec’s Sale of CGT Business
It is believed that both WuXi AppTec and WuXi ATU will continue to exert greater energy for more innovators and patients in need in the future
-
Gene editing therapy bombshell: A trial participant has died
many analysts are positive about Beam’s future
-
Eli Lilly Pipeline Analysis: Gene Therapy Products Accounts for 1/3, What Diseases Are Targeted?
DrugTimes will present more reports on CGT. Please stay tuned
